Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Abundio Balgos; Suad Hannawi; Wenli Chen; Alaa Abuquta; Linda Safeldin; Aala Hassan; Ahmad Alamadi; Louie Tirador; Anjuli May Jaen; Ralph Elvi Villalobos; Mo Chen; Zijing Yue; Ying Ma; Qingshuang Wang; Rendu Wen; Yao Zheng; Jiaping Yu; Wenrong Yao; Jianhui Zhang; Kunxue Hong; Yong Liu; Jingxin Li

doi:10.1080/14760584.2024.2334423

Abstract

Background Recombinant protein vaccines play a crucial role in providing broad immuno-protection against SARS-CoV-2 variants. This study evaluates the safety and immunogenicity of ReCOV as a booster dose in two randomized, observer-blinded, active-controlled Phase 2 clinical trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Balgos et al. (2024) studied this question.

synapsesocial.com/papers/68e7254ab6db64358769f1fb https://doi.org/10.1080/14760584.2024.2334423

View Full Paper

Ask AI

Bookmark

Share

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Abstract

Discussion

Cite This Study

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Abstract

Discussion

Cite This Study

Keep reading

Keep reading